French Startup raised €4M for Gene Therapy to fix specific Types of Blindness
Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M…
As one of the biggest success stories of the 21st century, gene therapy is providing hope for treating diseases that once seemed incurable. Any genetic mutation causing disease could theoretically be fixed by inserting a new copy of the faulty gene. This means that gene therapy has the potential to treat some previously incurable conditions with a single dose.
By 2025, the FDA expects to approve between 10 and 20 gene therapies each year, and we are already seeing an increase in the number of approvals today. However, the field continues to face a number of obstacles ranging from safety concerns to manufacturing shortages. Read on to get the latest in the gene therapy field.
Gene Therapy Industry Report 2021
In this report, we take a closer look at the growing gene therapy market, current development and manufacturing challenges, and the exciting future ahead for this industry.
Go to ReportHorama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M…
MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune…
Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP…
uniQure's Glybera was approved in Europe in 2012, making it the first gene therapy on…
Orchard Therapeutics has just been launched with a €26M investment led by a major investor.…
Production of CAR-T therapies seems to be one of the biggest challenge of this promising…
Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy…
With more than 200 types of cancer, the possibility of developing a Universal Cure is…
Quality of RNA and viral vectors used in clinical trials is subject to strict regulation.…
AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College…
The crisis of 2008 hit the Biotech sector hard, and it wasn't clear how the…
This multinational Phase III Trial for an Oncolytic Immunotherapy for Advanced Liver Cancer could be…